Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing innovative therapies to treat a variety of diseases, including cancer and autoimmune disorders
The company specializes in applying its proprietary drug delivery technology to enhance the efficacy and safety of existing therapies, as well as creating new treatments from the ground up. Nektar collaborates with other pharmaceutical organizations to advance its research pipeline and aims to address unmet medical needs by delivering transformative medicines that improve patients' lives.
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment.
Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair loss.
Shares of Bitdeer Technologies Group (NASDAQBTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
In this weekly outlook, I examine the asset classes, sectors, and ETFs that led the market higher, and which market segments bucked the trend by moving lower. Signs that market participation is broadening out are continuing to show up in the data.
Gainers Vistagen Therapeutics, Inc. (NASDAQVTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.
Keybanc raised the price target for Tempur Sealy International, Inc. (NYSETPX) from $48 to $50. Keybanc analyst Bradley Thomas maintained an Overweight rating. Tempur Sealy International shares rose 0.3% to $37.88 on Wednesday.
